BSW
RETA

Buckingham Strategic Wealth’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Buckingham Strategic Wealth’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,000
Closed -$289K – 490
2020
Q1 		$289K Hold
2,000
– – 0.03% 348
2019
Q4 		$409K Buy
+2,000
New +$365K 0.04% 285

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Buckingham Strategic Wealth's RETA Position: Q2 2020 in Review

Buckingham Strategic Wealth sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2020, closing a stake of 2,000 shares — an estimated $289K sold.

Buckingham Strategic Wealth first reported a position in RETA in Q4 2019 and held it in 2 quarters. The position peaked at $409K in Q4 2019. 207 funds tracked by Wall St. Rank hold RETA as of Q2 2020.

  • Buckingham Strategic Wealth reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2020 after selling out during the quarter.
  • Buckingham Strategic Wealth sold 2,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2020, an estimated $289K.
  • Buckingham Strategic Wealth first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 2 quarters.
  • Buckingham Strategic Wealth's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $409K in Q4 2019.
  • 207 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2020.

Based on Buckingham Strategic Wealth's 13F filing for Q2 2020, filed 3 Aug 2020.